Wuxi Lingfang Biopharmaceutical Technology

Wuxi Lingfang Biopharmaceutical Technology (Lingfang Pharmaceutical) is a clinical-stage biotechnology company based in Wuxi, China, specializing in the development of innovative targeted therapies for oncology. Founded in 2020 by Dr. Li Buyu, the company has rapidly established a pipeline of small molecule candidates designed to treat high-incidence solid tumors and hematological malignancies. Its lead programs include SC0011, an FGFR inhibitor in Phase 1b trials for gastric cancer, and LF0397, an ATR inhibitor in Phase 1 development. Lingfang leverages a combination of internal R&D and strategic licensing to build a differentiated portfolio, aiming to address significant unmet medical needs in the Chinese and global markets.